GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Long-Term Capital Lease Obligation

LAVA Therapeutics NV (LAVA Therapeutics NV) Long-Term Capital Lease Obligation : $0.39 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Long-Term Capital Lease Obligation?

LAVA Therapeutics NV's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.39 Mil.

LAVA Therapeutics NV's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($0.67 Mil) to Dec. 2023 ($0.59 Mil) and declined from Dec. 2023 ($0.59 Mil) to Mar. 2024 ($0.39 Mil).

LAVA Therapeutics NV's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.32 Mil) to Dec. 2022 ($0.43 Mil) and increased from Dec. 2022 ($0.43 Mil) to Dec. 2023 ($0.59 Mil).


LAVA Therapeutics NV Long-Term Capital Lease Obligation Historical Data

The historical data trend for LAVA Therapeutics NV's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Long-Term Capital Lease Obligation Chart

LAVA Therapeutics NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
0.26 0.27 0.32 0.43 0.59

LAVA Therapeutics NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.43 1.32 0.67 0.59 0.39

LAVA Therapeutics NV  (NAS:LVTX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

LAVA Therapeutics NV Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Industry
Traded in Other Exchanges
Address
Yalelaan 62, Utrecht, UT, NLD, 3584 CM
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.

LAVA Therapeutics NV (LAVA Therapeutics NV) Headlines